Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

被引：0

作者：

Parnis, F. ^{[1
]}

Rimassa, L. ^{[2
]}

Kelley, R. K. ^{[3
]}

Meyer, T. ^{[4
]}

Ryoo, B-Y ^{[5
]}

Merle, P. ^{[6
]}

Park, J-W ^{[7
]}

Blanc, J. F. ^{[8
]}

Lim, H-Y ^{[9
]}

Tran, A. ^{[10
]}

Borgman-Hagey, A. E. ^{[11
]}

Clary, D. O. ^{[11
]}

Wang, E. ^{[11
]}

Cheng, A-L ^{[12
]}

El-Khoueiry, A. B. ^{[13
]}

Abou-Alfa, G. K. ^{[14
]}

机构：

[1] Adelaide Canc Ctr, Adelaide, SA, Australia

[2] IRCCS, Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Milan, Italy

[3] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[4] Royal Free Hosp, London, England

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[6] Grp Hosp Lyon Nord, Lyon, France

[7] Natl Canc Ctr, Goyang, South Korea

[8] CHU Bordeaux, Hop Haut Leveque, Bordeaux, France

[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[10] Grp Hosp Archet, Hepatol, Nice, France

[11] Exelixis Inc, Alameda, CA USA

[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[13] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

340

引用

页码：180 / 181

页数：2